Transplantation for mantle cell lymphoma: is it the right thing to do?

Abstract

Mantle cell lymphoma (MCL) is a unique subtype of non-Hodgkin lymphoma that is both biologically and clinically heterogeneous. A variety of biomarkers, the achievement of minimal residual disease negativity after initial therapy, and the MCL International Prognostic Index (MIPI) are associated with patient outcome, although none has as yet been used for routine treatment stratification. Given the lack of widely accepted and standardized treatment approaches, clinical trial enrollment should always be considered for the initial therapy of MCL. Outside of the trial setting, younger and transplantation-eligible patients with newly diagnosed MCL who require treatment should first be considered for a rituximab ϩ a high-dose cytarabine-containing regimen, followed by autologous stem cell transplantation consolidation in first remission. Symptomatic elderly and nontransplantation-eligible individuals typically receive rituximab ϩ bendamustine, or R-CHOP (rituximab ϩ cyclophosphamide, hydroxydaunorubicin, vincristine, prednisone/ prednisolone) followed by maintenance rituximab, the latter a treatment plan that has demonstrated extended response duration and survival. Promising early results for consolidation approaches with proteasome inhibitors and immunomodulatory drugs are now being tested in randomized clinical trials. The availability of highly active BCR signaling pathway inhibitors and cell death pathway modulation via BH3 mimetics, among other novel agents, promise to rapidly expand treatment options, change existing treatment paradigms, and further improve outcomes for MCL patients.

Blood and Marrow Transplant Clinical Trials Network State of the Science Symposium 2014

“…Common induction regimens include R-CHOP or cytarabine-containing regimens, with younger patients often offered AuHCT in CR1 [24,25]. Recent reports show that maintenance rituximab after R-CHOP prolongs remission and reduces the risk of death in older patients [26].…”

Prognostic model for mantle cell lymphoma in the rituximab era: a nationwide study in Japan

“…Although the incidence of MCL appears to be increasing, it is still rare, accounting for only 2–5% of all lymphomas (Morton et al , ; Chihara et al , ). Most cases are diagnosed at an advanced stage and, despite progress in treatment, MCL remains essentially incurable with conventional chemotherapy, and prognosis remains poor (Vose, ; Williams, ).…”

Bortezomib-Based Therapy for Newly Diagnosed Mantle-Cell Lymphoma

“…1,2 It comprises 5 to 6% of all non-Hodgkin's lymphomas, including approximately 5000 cases per year in the United States. 3 For previously untreated patients who are either ineligible or not considered for intensive chemotherapy and stem-cell transplantation, R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) is a standard of care [4][5][6] and produces complete response rates of up to 48%. However, progression-free survival is limited (median, 16.6 months).…”